Rheumatic disorders in children, like juvenile arthritis and lupus, can damage joints and organs if untreated. Early ...

Rheumatic disorders, conditions caused by a dysregulated immune system, are prevalent among neonates and children. Speaking ...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

The idiopathic inflammatory myositis treatment market is poised for significant expansion, driven by the introduction of innovative targeted therapies and increasing disease awareness. Key idiopathic ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and ...